Tumor markers in metastatic breast cancer subtypes: Frequency of elevation and correlation with outcome

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 338-345

  Yerushalmi, R ^a   Tyldesley, S ^a   Kennecke, H ^a   Speers, C ^a   Woods, R ^a   Knight, B ^a   Gelmon, K A ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Breast cancer subtypes; CA 125; CA 15 3; CEA; Triple negative; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST CANCER SPECIFIC SURVIVAL; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MUCIN-1; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856338329     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr154     Document Type: Article

References (25)

1. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
2. Guadagni F, Ferroni P, Carlini S et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001; 7: 2357-2362.
3. Tondini C, Hayes DF, Gelman R et al. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988; 48: 4107-4112.
4. Lauro S, Trasatti L, Bordin F et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 1999; 19: 3511-3515.
5. Molina R, Jo J, Filella X et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998; 51: 109-119.
6. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82: 1535-1538.
7. Berruti A, Tampellini M, Torta M et al. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994; 30A: 2082-2084.
8. Baskic D, Ristic P, Matic S et al. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and HER2 in breast cancer. Biomarkers 2007; 12: 657-667.
9. Tampellini M, Berruti A, Gorzegno G et al. Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. Tumour Biol 2001; 22: 367-373.
10. Begic A, Kucukalic-Selimovic E, Obralic N et al. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma. Bosn J Basic Med Sci 2006; 6: 75-77.
11. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
12. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.
13. Kim HS, Park YH, Park MJ et al. Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat 2009; 118: 89-97.
14. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). Exp Oncol 2006; 28: 99-105.
15. Hayes DF, Ethier S, Lippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment. Breast Cancer Res Treat 2006; 100: 237-238.
16. Lindeman GJ, Visvader JE. Shedding light on mammary stem cells and tumorigenesis. Cell Cycle 2006; 5: 671-672.
17. Loprinzi CL, Tormey DC, Rasmussen P et al. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 1986; 4: 46-56.
18. Epiney M, Bertossa C, Weil A et al. CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000; 15: 1261-1265.
19. Daoud E, Bodor G. CA-125 concentrations in malignant and nonmalignant disease. Clin Chem 1991; 37: 1968-1974.
20. Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ 2009; 339: b3527.
21. Fehm T, Jager W, Kramer S et al. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 2004; 24: 1987-1992.
22. Ali SM, Leitzel K, Chinchilli VM et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002; 48: 1314-1320.
23. Singh R, Samant U, Hyland S et al. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther 2007; 6: 562-569.
24. Crow DM, Williams L, Colcher D et al. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjug Chem 2005; 16: 1117-1125.
25. Dorvillius M, Garambois V, Pourquier D et al. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen. Tumour Biol 2002; 23: 337-347.